Esophageal cancer is the eighth most common type of cancer worldwide and constitutes the
sixth leading cause of cancer deaths. It is characterized by its high mortality rate, poor …

Esophageal cancer (EC) is one of the most lethal cancers in the world, and its morbidity and
mortality rates rank among the top ten in China. Currently, surgical resection, radiotherapy …

Platinum-based chemotherapy is the standard first-line treatment for advanced esophageal
squamous cell carcinoma (ESCC). In this phase 3 study (ClinicalTrial. gov: NCT03829969) …

Background & Aims There were an estimated 4.8 million new cases of gastrointestinal (GI)
cancers and 3.4 million related deaths, worldwide, in 2018. GI cancers account for 26% of …

Background Chemotherapy for patients with advanced oesophageal squamous cell
carcinoma offers poor long-term survival prospects. We report the final analysis from our …

Background To investigate the safety and activity of preoperative pembrolizumab combined
with chemoradiotherapy for resectable oesophageal squamous cell carcinoma …

Background Programmed cell death 1 (PD-1) blockade induces tumor regression in patients
with advanced esophageal squamous cell carcinoma (ESCC); however, little is known about …

The tumor microenvironment is a highly complex ecosystem of diverse cell types, which
shape cancer biology and impact the responsiveness to therapy. Here, we analyze the …

Importance Safety and efficacy of neoadjuvant chemoradiotherapy (nCRT) vs neoadjuvant
chemotherapy (nCT) for treatment of locally advanced esophageal squamous cell …

Background Esophageal cancer is the sixth leading cause of cancer-related deaths and the
eighth most common cancer worldwide with a 5-year survival rate of less than 25%. Here we …